Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Overview
Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Companies Involved in Therapeutics Development
Bristol-Myers Squibb Co
Cadent Therapeutics Inc
Cerecor Inc
Johnson & Johnson
NeurOp Inc
Novartis AG
Shionogi & Co Ltd
Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Drug Profiles
BMS-986163 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAD-8688 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ifenprodil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-0808 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neu-2000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NP-10679 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rislenemdaz - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize NR2B for Depression - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize GRIN2B for Autism and Obsessive Compulsive Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize NMDA2B for Chronic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize NR2B for Neuropathic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Dormant Products
Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Discontinued Products
Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Product Development Milestones
Featured News & Press Releases
Feb 15, 2019: Cerecor announces CERC-301 granted U.S. patent
Aug 01, 2018: Cerecor announces first patient enrolled in phase I trial for neurogenic orthostatic hypotension (noh) in Parkinson’s disease
Apr 12, 2018: NeurOp Initiates Phase 1 Clinical Trial of NMDA Receptor Inhibitor NP10679
Oct 17, 2017: Cadent Therapeutics Receives Milestone for the Initiation of Phase 1 Clinical Studies
Jul 24, 2017: NIH Awards NeurOp $3.5 Million to Support Phase 1 Clinical Trial of NMDA Inhibitor NP10679
Nov 29, 2016: Cerecor Reports Top-Line Data from CERC-301 Phase 2 Study for Major Depressive Disorder
Sep 21, 2016: Cerecor Announces Completion of Enrollment in Phase 2 Clinical Trial with CERC-301 as an Oral, Adjunctive Treatment of Major Depressive Disorder
May 16, 2016: GNT Pharma Receives IND Approval for Phase II Clinical Trial for Stroke Patients with Endovascular Treatment with First in Class Multi-Target Neuroprotection Drug Neu2000
Jan 19, 2016: Cerecor Announces Publication Describing Antidepressant Activity of CERC-301 in Preclinical Model
Sep 03, 2015: Cerecor Initiates Phase 2 Study for CERC-301, an Antidepressant Product Candidate with Potential for Rapid Onset of Effect
Mar 20, 2015: Cerecor Provides Update on CERC-301 Development in Major Depressive Disorder
Oct 03, 2014: Cerecor to Present at 13th Annual BIO Investor Forum
Dec 02, 2013: MedAvante Central Ratings Selected For Cerecor Investigatiol MDD Study
Nov 25, 2013: Cerecor Receives Fast Track Desigtion for CERC-301 for the Treatment of Major Depressive Disorder
Nov 08, 2013: Cerecor Announces Initiation of Phase 2 Study for CERC-301, an Oral Rapid-acting Antidepressant Candidate
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019


List of Tables


Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indication, H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by Bristol-Myers Squibb Co, H1 2019
Pipeline by Cadent Therapeutics Inc, H1 2019
Pipeline by Cerecor Inc, H1 2019
Pipeline by Johnson & Johnson, H1 2019
Pipeline by NeurOp Inc, H1 2019
Pipeline by Novartis AG, H1 2019
Pipeline by Shionogi & Co Ltd, H1 2019
Dormant Projects, H1 2019
Discontinued Products, H1 2019